Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1682 1758
This examiner grants 43% of resolved cases
Bailey Cheyenne Buchanan examines applications in Tech Center 1700 and Art Unit 1682. Her data includes 28 resolved cases, which result in an allowance rate pct of 42.9. This indicates that less than half of the cases she resolves are granted. The median days to allowance for those that are successful is 1369, reflecting the period from filing to the final grant for applications in her unit.
The interview lift pct of 57.1 is a significant factor for strategy. This figure shows that interviews are associated with a large increase in the probability of allowance. In Art Unit 1682, the 57.1 interview lift pct suggests that oral advocacy is one of the most effective tools available to practitioners to overcome the challenges reflected in the 42.9 allowance rate pct.
With 28 resolved cases, the examiner's trends are documented. The 1369 median days to allowance suggests that patience is required during prosecution. However, the 57.1 interview lift pct provides a clear path for improving the 42.9 allowance rate pct, making interviews a critical step for any applicant working within Tech Center 1700. The 1369 median days to allowance serves as the primary timing benchmark.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18689573 | MASTER MIX COMPOSITIONS, KITS, AND METHODS | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 17559511 | METHODS AND COMPOSITIONS FOR ANALYTE DETECTION | Non-Final OA | 10x Genomics, Inc. |
| 17768786 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER | Non-Final OA | The Regents of the University of California |
| 18298922 | TRANSMEMBRANE NANOSENSOR ARRAYS FOR RAPID, ULTRA-SENSITIVE AND SPECIFIC DIGITAL QUANTIFICATION OF INTERNAL MICRO-RNA CONTENT OF INTACT EXOSOMES | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18343097 | ASSESSING TRANSPLANT COMPLICATION RISK WITH TOTAL CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin Inc. |
| 18028432 | NUCLEIC ACID NANOSTRUCTURES WITH TUNABLE FUNCTIONAL STABILITY | Final Rejection | National University of Singapore |
| 18245749 | SIGNATURES IN CELL-FREE DNA TO DETECT DISEASE, TRACK TREATMENT RESPONSE, AND INFORM TREATMENT DECISIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 17687536 | METHODS AND RELATED ASPECTS FOR ANALYZING MOLECULAR RESPONSE | Final Rejection | GUARDANT HEALTH, INC. |
| 18002270 | MOLECULAR SIGNATURE OF A COMMON ALOPECIC STATE, ASSOCIATED WITH CELL JUNCTIONS | Final Rejection | L'OREAL |
| 17716381 | ENRICHMENT OF CELL-FREE DNA FROM A BIOLOGICAL SAMPLE | Non-Final OA | MYRIAD WOMEN'S HEALTH, INC. |
| 17780926 | UPPER URINARY TRACT UROTHELIAL CARCINOMA IDENTIFICATION METHOD | Non-Final OA | KEIO UNIVERSITY |
| 18700295 | COMPOSITION FOR DIAGNOSING PERIODONTAL DISEASE USING BACTERIAL POPULATION IN SALIVA, AND USE THEREOF | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17760652 | HUMAN MITOCHONDRIAL DNA SEQUENCING BY TARGETED AMPLIFICATION OF MULTIPLEX PROBES (MTDNA-STAMP) | Final Rejection | CORNELL UNIVERSITY |
| 17890694 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17632783 | CANCER DETECTION AND CLASSIFICATION | Final Rejection | The United States of America, as represented by the Secretary, Department of Health and Human Servic |
| 17384241 | DETECTING CANCER, CANCER TISSUE OF ORIGIN, AND/OR A CANCER CELL TYPE | Final Rejection | GRAIL, LLC |
| 17624791 | DETERMINING INDIVIDUAL HLA PATTERNS, USE AS PROGNOSTICATORS, TARGET GENES AND THERAPEUTIC AGENTS | Final Rejection | INTELLEXON GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy